Headquartered in Brisbane, CA Fiscal year ends November NASDAQ: NRIX nurixtx.com
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for patients with cancer and autoimmune diseases. The company's clinical oncology pipeline centers on degraders of Bruton's tyrosine kinase (BTK) — led by bexobrutideg, now being co-developed and co-commercialized with Roche — and inhibitors of CBL-B, an E3 ligase regulating immune cell activation. Nurix also advances preclinical degraders and degrader antibody conjugates (DACs). Its autoimmune pipeline includes a clinical-stage IRAK-4 degrader in collaboration with Gilead and a preclinical STAT6 degrader with Sanofi. Additional programs are pursued under collaborations with Pfizer. The company's AI-integrated discovery engine is designed to tackle diverse protein targets, leveraging deep expertise in ligase biology to translate targeted protein degradation science into clinical-stage drug candidates across oncology, immunology, and neurology. Updated
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for patients with cancer and autoimmune diseases.
The Wall Street consensus 12-month price target for NRIX is $33.93.
